Speaker Profile
M.D., CEO, Buck Inst.
Biography
Verdin’s laboratory focuses on the role of epigenetic regulators in the aging process. His laboratory was the first to clone a family of enzymes, called HDACs, which regulate histone acetylation. Verdin studies how metabolism, diet and small molecules regulate the activity of HDACs and Sirtuins and thereby the aging process and its associated diseases, including Alzheimer’s. He has published more than 210 scientific papers and holds more than 15 patents. He is a highly cited scientist (top 1%) and has been recognized for his research with a Glenn Award for Research in Biological Mechanisms of Aging and a senior scholarship from the Ellison Medical Foundation. He is an elected member of several scientific organizations including the American Association for the Advancement of Science, the American Society for Clinical Investigation and the Association of American Physicians. He also serves on the Advisory Council of NIDA at the National Institutes of Health.
He has held faculty positions at the University of Brussels, the National Institutes of Health (NIH), and the Picower Institute for Medical Research. Dr. Verdin is also a Professor of Medicine at the University of California, San Francisco.
Eric received his Doctorate of Medicine (MD) from the University of Liege and additional clinical and research training at Harvard Medical School.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Michael Goldman, SFSU
PMWC Award Ceremony
• David Sinclair, Harvard
• Steve Horvath, Altos Labs
• Nir Barzilai, Albert Einstein College of Medicine
AI-Driven Biomarkers to Quantify Aging
• Chair: Alex Zhavoronkov, Insilico Medicine
• Mahdi Moqri, Harvard
• Steve Horvath, Altos Labs
• Hussain Ahamed, Ultrahuman
Epigenetic Aging Signatures in Large Human Cohorts
• Varun Dwaraka, TruDiagnostic
AI Systems for Personalized Longevity: How Biomarkers Translate into Actionable Interventions
• Chair: Nathan Price, Buck Institute
• Sherry Zhang, Buck Institute
• Ranjan Sinha, Digbi Health
• Zeenia Framroze, Alethios, Inc.
• John Ramunas, Rejuvenation Technologies
Clinical Trial Design & Functional Endpoints for Healthspan
• Nir Barzilai, Albert Einstein College of Mediciney
The data We Need For AI To Accelerate Longevity Drugs
• Martin Jensen, Gordian Biotechnology
From Genome to an AI-Drive Longevity Platform
• Wei-Wu He, Human Longevity
Wellness Wearables: The Journey to Clinical
• Hussain Ahamed, Ultrahuman
Longevity Medicine: Ambition vs Evidence in the Era of Precision Health
• Aubrey de Grey, LEV Foundation
Precision Aging & Longevity Focused on Limited Lifespan Evidence, Vanishing Blue Zones, and Payer ROI
• S. Jay Olshansky, University of Illinois
Evolutionary perspectives on human lifespan and healthspan
• Michael Gurven, UC Santa Barbara
